Non-Alcoholic Fatty Liver Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have type 2 diabetes and your doctor is planning to start you on a combination pill containing dapagliflozin and pioglitazone at your first study visit.
- You are willing to voluntarily sign a written agreement allowing your personal information to be used for this study, after being fully informed about its purpose and methods.
Who may not be able to join:
- You have previously taken the combination pill containing dapagliflozin and pioglitazone before your first study visit.
- You are expected to need insulin treatment at any point during the study period.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +82-2-708-8000
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Percentage of subjects who correspond to high risk score (≥8) by evaluating simple NAFLD score
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.